Agnès Belkacem, Katie M Lavigne, Carolina Makowski, Mallar Chakravarty, Ridha Joober, Ashok Malla, Jai Shah, Martin Lepage
{"title":"抗胆碱能负荷对首发精神病言语记忆表现的影响。","authors":"Agnès Belkacem, Katie M Lavigne, Carolina Makowski, Mallar Chakravarty, Ridha Joober, Ashok Malla, Jai Shah, Martin Lepage","doi":"10.1177/07067437231179161","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Antipsychotics are widely used to treat first-episode psychosis but may have an anticholinergic burden, that is, a cumulative effect of medications that block the cholinergic system. Studies suggest that a high anticholinergic burden negatively affects memory in psychosis, where cognitive deficits, particularly those in verbal memory, are a core feature of the disease. The present study sought to replicate this in a large cohort of well-characterized first-episode psychosis patients. We expected that patients in the highest anticholinergic burden group would exhibit the poorest verbal memory compared to those with low anticholinergic burden and healthy controls at baseline (3 months following admission). We further hypothesized that over time, at month 12, patients' verbal memory performance would improve but would remain inferior to controls.</p><p><strong>Methods: </strong>Patients (<i>n</i> = 311; low anticholinergic burden [<i>n</i> = 241] and high anticholinergic burden [<i>n</i> = 70], defined by a Drug Burden Index cut-off of 1) and healthy controls (<i>n</i> = 128) completed a clinical and neurocognitive battery including parts of the Wechsler Memory Scale at months 3 and 12.</p><p><strong>Results: </strong>Cross-sectionally, using an analysis of variance, patients in the highest anticholinergic burden group had the poorest performance in verbal memory when compared to the other groups at month 3, <i>F</i>(2,430) = 52.33, <i>P</i> < 0.001. Longitudinally, using a Generalized Estimating Equation model, the verbal memory performance of all groups improved over time. However, patients' performance overall remained poorer than the controls.</p><p><strong>Conclusion: </strong>These findings highlight the importance of considering the anticholinergic burden when prescribing medications in the early stages of the disease.</p>","PeriodicalId":55283,"journal":{"name":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","volume":" ","pages":"894-903"},"PeriodicalIF":3.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657580/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Anticholinergic Burden on Verbal Memory Performance in First-Episode Psychosis.\",\"authors\":\"Agnès Belkacem, Katie M Lavigne, Carolina Makowski, Mallar Chakravarty, Ridha Joober, Ashok Malla, Jai Shah, Martin Lepage\",\"doi\":\"10.1177/07067437231179161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Antipsychotics are widely used to treat first-episode psychosis but may have an anticholinergic burden, that is, a cumulative effect of medications that block the cholinergic system. Studies suggest that a high anticholinergic burden negatively affects memory in psychosis, where cognitive deficits, particularly those in verbal memory, are a core feature of the disease. The present study sought to replicate this in a large cohort of well-characterized first-episode psychosis patients. We expected that patients in the highest anticholinergic burden group would exhibit the poorest verbal memory compared to those with low anticholinergic burden and healthy controls at baseline (3 months following admission). We further hypothesized that over time, at month 12, patients' verbal memory performance would improve but would remain inferior to controls.</p><p><strong>Methods: </strong>Patients (<i>n</i> = 311; low anticholinergic burden [<i>n</i> = 241] and high anticholinergic burden [<i>n</i> = 70], defined by a Drug Burden Index cut-off of 1) and healthy controls (<i>n</i> = 128) completed a clinical and neurocognitive battery including parts of the Wechsler Memory Scale at months 3 and 12.</p><p><strong>Results: </strong>Cross-sectionally, using an analysis of variance, patients in the highest anticholinergic burden group had the poorest performance in verbal memory when compared to the other groups at month 3, <i>F</i>(2,430) = 52.33, <i>P</i> < 0.001. Longitudinally, using a Generalized Estimating Equation model, the verbal memory performance of all groups improved over time. However, patients' performance overall remained poorer than the controls.</p><p><strong>Conclusion: </strong>These findings highlight the importance of considering the anticholinergic burden when prescribing medications in the early stages of the disease.</p>\",\"PeriodicalId\":55283,\"journal\":{\"name\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"volume\":\" \",\"pages\":\"894-903\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657580/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/07067437231179161\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/07067437231179161","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Effects of Anticholinergic Burden on Verbal Memory Performance in First-Episode Psychosis.
Objectives: Antipsychotics are widely used to treat first-episode psychosis but may have an anticholinergic burden, that is, a cumulative effect of medications that block the cholinergic system. Studies suggest that a high anticholinergic burden negatively affects memory in psychosis, where cognitive deficits, particularly those in verbal memory, are a core feature of the disease. The present study sought to replicate this in a large cohort of well-characterized first-episode psychosis patients. We expected that patients in the highest anticholinergic burden group would exhibit the poorest verbal memory compared to those with low anticholinergic burden and healthy controls at baseline (3 months following admission). We further hypothesized that over time, at month 12, patients' verbal memory performance would improve but would remain inferior to controls.
Methods: Patients (n = 311; low anticholinergic burden [n = 241] and high anticholinergic burden [n = 70], defined by a Drug Burden Index cut-off of 1) and healthy controls (n = 128) completed a clinical and neurocognitive battery including parts of the Wechsler Memory Scale at months 3 and 12.
Results: Cross-sectionally, using an analysis of variance, patients in the highest anticholinergic burden group had the poorest performance in verbal memory when compared to the other groups at month 3, F(2,430) = 52.33, P < 0.001. Longitudinally, using a Generalized Estimating Equation model, the verbal memory performance of all groups improved over time. However, patients' performance overall remained poorer than the controls.
Conclusion: These findings highlight the importance of considering the anticholinergic burden when prescribing medications in the early stages of the disease.
期刊介绍:
Established in 1956, The Canadian Journal of Psychiatry (The CJP) has been keeping psychiatrists up-to-date on the latest research for nearly 60 years. The CJP provides a forum for psychiatry and mental health professionals to share their findings with researchers and clinicians. The CJP includes peer-reviewed scientific articles analyzing ongoing developments in Canadian and international psychiatry.